CenterBook Partners LP lessened its holdings in shares of Merus N.V. (NASDAQ:MRUS - Free Report) by 36.2% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 91,088 shares of the biotechnology company's stock after selling 51,787 shares during the period. CenterBook Partners LP owned approximately 0.13% of Merus worth $3,834,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Wells Fargo & Company MN lifted its position in Merus by 27.3% during the fourth quarter. Wells Fargo & Company MN now owns 1,400 shares of the biotechnology company's stock valued at $59,000 after purchasing an additional 300 shares during the period. GF Fund Management CO. LTD. increased its holdings in Merus by 21.9% in the first quarter. GF Fund Management CO. LTD. now owns 1,753 shares of the biotechnology company's stock valued at $74,000 after buying an additional 315 shares in the last quarter. Parkman Healthcare Partners LLC increased its holdings in Merus by 0.7% in the fourth quarter. Parkman Healthcare Partners LLC now owns 45,680 shares of the biotechnology company's stock valued at $1,921,000 after buying an additional 331 shares in the last quarter. Knights of Columbus Asset Advisors LLC increased its holdings in Merus by 2.7% in the first quarter. Knights of Columbus Asset Advisors LLC now owns 13,785 shares of the biotechnology company's stock valued at $580,000 after buying an additional 361 shares in the last quarter. Finally, Deutsche Bank AG increased its holdings in Merus by 0.4% in the fourth quarter. Deutsche Bank AG now owns 113,056 shares of the biotechnology company's stock valued at $4,754,000 after buying an additional 416 shares in the last quarter. 96.14% of the stock is currently owned by institutional investors and hedge funds.
Insider Transactions at Merus
In other news, COO Peter B. Silverman sold 16,805 shares of the firm's stock in a transaction on Thursday, July 10th. The shares were sold at an average price of $55.00, for a total value of $924,275.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last quarter, insiders have sold 57,500 shares of company stock worth $3,086,340. 4.57% of the stock is owned by corporate insiders.
Analyst Ratings Changes
A number of research analysts have weighed in on MRUS shares. Guggenheim reaffirmed a "buy" rating and issued a $109.00 price objective on shares of Merus in a report on Friday, March 28th. Needham & Company LLC reaffirmed a "buy" rating and issued a $75.00 price objective on shares of Merus in a report on Monday, May 19th. Wall Street Zen raised shares of Merus from a "sell" rating to a "hold" rating in a research note on Saturday, July 12th. William Blair restated an "outperform" rating on shares of Merus in a research report on Monday, April 28th. Finally, Wells Fargo & Company lowered their price target on shares of Merus from $91.00 to $89.00 and set an "overweight" rating on the stock in a research report on Thursday, May 8th. One equities research analyst has rated the stock with a hold rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat.com, Merus currently has a consensus rating of "Buy" and an average target price of $84.64.
View Our Latest Stock Analysis on Merus
Merus Stock Up 3.0%
Merus stock traded up $1.82 during mid-day trading on Friday, reaching $63.26. 1,061,440 shares of the company's stock were exchanged, compared to its average volume of 910,994. The company has a market cap of $4.38 billion, a P/E ratio of -15.50 and a beta of 1.00. Merus N.V. has a twelve month low of $33.19 and a twelve month high of $63.43. The company has a fifty day moving average of $52.03 and a 200-day moving average of $46.02.
Merus (NASDAQ:MRUS - Get Free Report) last released its earnings results on Wednesday, May 14th. The biotechnology company reported ($1.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.23). The business had revenue of $26.49 million for the quarter, compared to analyst estimates of $7.82 million. Merus had a negative return on equity of 35.99% and a negative net margin of 506.73%. Equities research analysts expect that Merus N.V. will post -3.85 earnings per share for the current fiscal year.
Merus Company Profile
(
Free Report)
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.
Further Reading
Before you consider Merus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merus wasn't on the list.
While Merus currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
